← Evidence map

ArticleFrontiers in pharmacology2026

Furmonertinib demonstrated efficacy in a case of advanced pancreatic cancer with a 19-exon deletion mutation and wild-type KRAS: a case report and literature review.

Fengcai Du et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Furmonertinib demonstrated efficacy in a case of advanced pancreatic cancer with a 19-exon deletion mutation and wild-type KRAS: a case report and literature review. | OpenQuestion